Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
NCT00717509 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2009-06-12
Summary
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
Conditions
- Schizophrenia
- Metabolic Syndrome
- Genetic Polymorphism
Sponsors & Collaborators
-
Seoul National Hospital
lead OTHER_GOV
Principal Investigators
-
Shi Hyun Kang, M.D. · Seoul National Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-10-31
- Primary Completion
- 2009-01-31
- Completion
- 2009-10-31
Countries
- South Korea
Study Locations
More Related Trials
-
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
NCT02964923 ·Status: UNKNOWN
-
Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea
NCT01477918 ·Status: UNKNOWN
-
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169039 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
NCT00250575 ·Status: COMPLETED ·Phase: PHASE3
-
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
NCT01663077 ·Status: COMPLETED ·Phase: PHASE4
-
Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication
NCT00698295 ·Status: UNKNOWN
-
Serum Clozapine and Cognition
NCT00951418 ·Status: COMPLETED
-
A Positional Cloning Study on Schizophrenia
NCT00155649 ·Status: COMPLETED
-
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932 ·Status: COMPLETED ·Phase: NA
-
Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
NCT02248987 ·Status: COMPLETED
-
CVN058 Effect on Mismatch Negativity in Schizophrenics
NCT03669250 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.
NCT00945503 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
NCT00455702 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
NCT02205099 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
NCT01160679 ·Status: COMPLETED
-
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
NCT00937755 ·Status: COMPLETED
-
A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
NCT01075373 ·Status: UNKNOWN
-
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome
NCT04518319 ·Status: SUSPENDED ·Phase: PHASE2
-
Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment
NCT00707382 ·Status: COMPLETED ·Phase: NA
-
fMRI Cholinergic Mechanisms in Schizophrenia
NCT01191827 ·Status: COMPLETED
-
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
NCT00584519 ·Status: COMPLETED
-
Evaluation of Metamemory in Patients With Schizophrenia
NCT03338179 ·Status: COMPLETED ·Phase: NA
-
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia
NCT01943175 ·Status: COMPLETED
-
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
NCT02714894 ·Status: UNKNOWN